Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05699759 · ClinicalTrials.gov registry record · Phase 1
Safety and Effect of Intravitreal Injection of a Derivative of Nucleoside Reverse Transcriptase Inhibitor in Subjects with Diabetic Macular Edema
A Phase 1 study, sponsored by Michelle Abou-Jaoude.
- Completed
- Registry status
- Phase 1
- Development phase
- 1
- Enrollment target
NCT05699759 is a Phase 1 study that has completed, run by Michelle Abou-Jaoude. The registered enrollment target is 1 participants.
The verdict
NCT05699759, a Phase 1 study, has completed, sponsored by Michelle Abou-Jaoude.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 1 participants
- Enrollment target
Study Summary
This study is designed to assess the safety and initial evidence of efficacy of the novel compound SOM-401 (K8), a derivative of a nucleoside reverse transcriptase inhibitor, in subjects with untreated, clinically significant, diabetic macular edema (DME).
Interventions
- DRUG K8
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2024-01-04 |
| Est. Completion | 2024-06-20 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05699759
The ClinicalTrials.gov registry entry for NCT05699759 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Michelle Abou-Jaoude, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which K8 is the first listed.
NCT05699759 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05699759 about?
NCT05699759 is a clinical study titled "Safety and Effect of Intravitreal Injection of a Derivative of Nucleoside Reverse Transcriptase Inhibitor in Subjects with Diabetic Macular Edema". This study is designed to assess the safety and initial evidence of efficacy of the novel compound SOM-401 (K8), a derivative of a nucleoside reverse transcriptase inhibitor, in subjects with untreated, clinically significant, diabetic macular edema (DME).
What is the current status of trial NCT05699759?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 1 participants. The study started on 2024-01-04. Estimated completion is 2024-06-20.
What interventions are being tested in trial NCT05699759?
The interventions under investigation include: K8 (DRUG).
Who is sponsoring clinical trial NCT05699759?
This trial is sponsored by Michelle Abou-Jaoude, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.